AlphaThera

Executive Summary

AlphaThera is a San Francisco-based biotechnology company developing and selling site-specific antibody labeling reagents through its proprietary oYo-Link technology. Founded in 2017, the company enables rapid and simple conjugation of antibodies to diverse payloads including oligonucleotides, enzymes, fluorescent dyes, drugs, and biotin. Serving the research, diagnostic, and therapeutic development markets, AlphaThera's technology is particularly relevant for oncology applications, where precise antibody-drug conjugates (ADCs) and imaging agents are critical. The oYo-Link platform addresses a key bottleneck in bioconjugation by offering a versatile, easy-to-use solution that maintains antibody functionality, positioning the company as an enabler for both academic researchers and biopharma developers. As a private early-stage company, AlphaThera's growth trajectory depends on expanding its commercial footprint and securing partnerships. The global antibody labeling market is growing, driven by demand for ADCs and multiplexed assays. However, competition from established players like Thermo Fisher and newer startups necessitates differentiation. AlphaThera's strategic focus on oncology and its open-platform approach could drive adoption, but revenue figures and funding history remain undisclosed. The company is likely to seek Series A funding or strategic collaborations to scale production and validate its technology for therapeutic use. If successful, oYo-Link could become a standard tool in antibody engineering, though execution risks persist.

Upcoming Catalysts (preview)

• Q2 2026Series A Funding Announcement70% success
• Q4 2025Partnership with a Top 10 Pharma for ADC Development40% success
• Q3 2026Launch of oYo-Link for Therapeutic Antibody Conjugation60% success